Immunoglobulin (SCIG)
Primary Immunodeficiencies
Phase 3 / RegistrationActive
Key Facts
About Kedrion Biopharma
Kedrion Biopharma is a significant global player in the plasma-derived therapeutics sector, operating a network of plasma collection centers and fractionation facilities. The company's product portfolio includes immunoglobulins, albumin, clotting factors, and hyperimmune globulins, which are critical for patients with rare and chronic conditions. As a private company, it competes in a consolidated market dominated by a few large firms, leveraging its integrated supply chain from plasma collection to final product distribution. Its strategic focus is on expanding its geographic footprint and product pipeline to address growing global demand for plasma therapies.
View full company profileTherapeutic Areas
Other Primary Immunodeficiencies Drugs
| Drug | Company | Phase |
|---|---|---|
| Subcutaneous Immunoglobulin (SCIG) | Shanghai RAAS Blood Products | Registration |
| HyQvia® (with Takeda) | Halozyme Therapeutics | Approved |